The synergistic anti-neoplastic efficacy of combined MEK and mTOR inhibitors has been demonstrated in melanoma, lung, and colorectal cancer, where it resulted in profound tumor cell apoptosis and inhibition of tumor cell proliferation [37,38]. Here, MAP2K7 is linked to melanoma.